April 21, 2021

CASE Statement:
As a leading advocate for consumers and patients across the country, Consumer Action for a Strong Economy (CASE) continues to call for Congress to reject dangerous price control proposals and instead support the free market provisions in H.R. 19, the Lower Costs, More Cures Act.

“For years, lawmakers have tried to pass H.R. 3, which pushes dangerous international price controls and Medicare negotiation schemes identical to failing systems abroad,” said Matthew Kandrach, CASE President. “Now as Democrats consider reintroducing this harmful legislation to pay for the President’s broad infrastructure and American Families Plan, the threat against American innovation could not be more real. The Lower Costs, More Cures Act, on the other hand, is a bipartisan compromise that promotes transparency and cost savings for patients at the pharmacy counter. While additional measures are still needed to bolster America’s private sector and more effectively lower prices, this bill is a step in the right direction.”

“CASE urges lawmakers to support these types of market- based solutions to lowering costs for consumers and continue to oppose dangerous price controls
that will reduce patient access, stymie innovation and lead to fewer cures.”